Jagdeep Kahlon, MD
Psychiatry · Midlothian, VANPI 1669633319
Payments from drug & device makers
Across 324 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$946
- Johnson & Johnson$851
- Lundbeck LLC$518
- E.r. Squibb & Sons, L.L.C.$509
- plus $2K from 16 others
What the payments were for
- Food & beverage$8,25099%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 39 | $1,662 |
| AbbVie(2 entities) | 63 | $1,412 |
| Neurocrine Biosciences, Inc. | 25 | $946 |
| Johnson & Johnson | 26 | $851 |
| Lundbeck LLC | 28 | $518 |
| E.r. Squibb & Sons, L.L.C. | 19 | $509 |
| Teva Pharmaceuticals USA, Inc. | 24 | $475 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $458 |
| Sunovion Pharmaceuticals Inc. | 18 | $329 |
| Alkermes, Inc. | 12 | $244 |
| Axsome Therapeutics, Inc. | 7 | $223 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $180 |
| Eisai Inc. | 5 | $87 |
| Corium, LLC | 3 | $83 |
| Almatica Pharma LLC | 4 | $72 |
| Merck | 4 | $66 |
| Bioxcel Therapeutics, Inc. | 3 | $61 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| Tris Pharma Inc | 2 | $34 |
| TMS Neurohealth Centers Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$517
- VRAYLAR$365
- REXULTI$362
- COBENFY$255
- ABILIFY MAINTENA$242
- Austedo XR$126
- ABILIFY ASIMTUFII$125
- LATUDA$114
- INVEGA SUSTENNA$107
How this compares
$8,309 in reported general payments places this provider in the 90th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $155,412 |
| Invega SustennaPaliperidone Palmitate | 25 | $79,616 |
| TrintellixVortioxetine Hydrobromide | 35 | $28,503 |
| RexultiBrexpiprazole | 12 | $17,353 |
| Aripiprazole | 155 | $13,734 |
| BelsomraSuvorexant | 20 | $8,712 |
| Lurasidone Hcl | 50 | $5,458 |
| Guanfacine Hcl ErGuanfacine Hcl | 12 | $3,744 |
| Hydroxyzine Hcl | 204 | $3,302 |
| Bupropion XlBupropion Hcl | 94 | $2,865 |
| Eszopiclone | 65 | $1,974 |
| Atomoxetine Hcl | 19 | $1,619 |
| Clozapine | 43 | $1,608 |
| Buspirone Hcl | 106 | $1,545 |
| Olanzapine | 50 | $1,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $946 | $155,41219 claims |
| Johnson & JohnsonInvega Sustenna | $851 | $79,61625 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $458 | $28,50335 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,662 | $17,35312 claims |
| MerckBelsomra | $66 | $8,71220 claims |
| Almatica Pharma LLCSertraline Hcl | $72 | $55966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Midlothian
- Rehan SaleemMidlothian$28K
- Adam KaulMidlothian$20K
- Kemberly ClarkMidlothian$11K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- Frederick MoellerRichmond$678K
- David SpiegelNorfolk$565K
- Christopher van EyckStafford$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.